HSA | FSA CARDS ARE NOW ACCEPTED

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on peptide genetics and GLP-1 pathways. Browse all Peptides & GLP-1 education →

When a clinical trial compares a new drug against an active comparator that already has proven cardiovascular benefits, the headline result can be misleading — not because the data is wrong, but because the math is incomplete. That's precisely the situation with SURPASS-CVOT, and a new analysis published in Diabetes Care sets out to fill the gap.

What SURPASS-CVOT Actually Measured

The SURPASS-CVOT trial enrolled 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD) across 640 sites in 30 countries. Participants were randomized to either tirzepatide — a dual GIP and GLP-1 receptor agonist — or dulaglutide, a GLP-1 receptor agonist with its own well-documented cardiovascular benefit. The trial ran for a median of 4.5 years, making it the longest and largest study of tirzepatide to date.

The primary outcome was time to first major adverse cardiovascular event (MACE), defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Tirzepatide met the trial's primary objective of non-inferiority, with a hazard ratio of 0.92 (95.3% CI, 0.83–1.01) compared to dulaglutide. All-cause mortality was reduced by 16% (HR 0.84; 95% CI 0.75–0.94; P=.002). Tirzepatide also delivered meaningfully greater reductions in HbA1c (–1.73% vs. –0.90%) and body weight (12% vs. 4.95%) compared to dulaglutide at 36 months.

The Active Comparator Problem: Why the Trial Design Matters

Here's the issue the Diabetes Care analysis addresses directly: dulaglutide is not a placebo. It is a GLP-1 receptor agonist with established cardiovascular protection. By choosing dulaglutide as the comparator — a decision made for ethical and scientific reasons, since withholding a cardioprotective drug from a high-risk population raises valid concerns — SURPASS-CVOT was effectively measuring whether tirzepatide is at least as good as an already-effective treatment.

That design answers an important regulatory question. But it cannot answer the question patients, clinicians, and researchers actually want answered: how much cardiovascular benefit does tirzepatide provide compared to no GLP-1 treatment at all? The 8% MACE reduction seen in SURPASS-CVOT reflects the difference between two active treatments, not the absolute benefit of tirzepatide over a true control.

The Imputed Placebo Analysis: Estimating the True Benefit

The Diabetes Care study (2026; doi:10.2337/dc26-0298) addresses this using an indirect treatment comparison. The authors identified a REWIND Target Population — a subset of 1,934 REWIND participants whose baseline characteristics matched SURPASS-CVOT inclusion criteria — and applied propensity score-based adjustment using stabilized inverse-probability weighting to create a comparable control group. This methodological rigor is important: rather than importing all of REWIND's 9,901 participants wholesale, the analysis used matched subgroups to make a more valid apples-to-apples indirect comparison. Diabetes Care, 2026

The results across four cardiovascular endpoints in the primary propensity score-adjusted analysis:

  • MACE-3 (CV death, MI, or stroke): HR 0.72 (95% CI 0.55–0.94), p=0.016 — a 28% reduction vs. theoretical placebo
  • All-cause death: HR 0.61 (95% CI 0.45–0.82), p=0.001 — a 39% reduction vs. theoretical placebo
  • CV death or heart failure: HR 0.70 (95% CI 0.51–0.96), p=0.025 — a 30% reduction vs. theoretical placebo
  • MACE-4 (MACE-3 plus unstable angina): HR 0.80 (95% CI 0.64–1.01), p=0.057 — borderline significant

Sensitivity analyses run without propensity score adjustment produced consistent results — MACE-3 HR 0.72 (p=0.005) and all-cause death HR 0.70 (p=0.005) — supporting the robustness of the primary findings across analytical approaches.

These are indirect treatment comparison estimates, not direct placebo-controlled trial results. The authors appropriately frame them as hypothesis-generating — a rigorous way to contextualize what the SURPASS-CVOT active comparator design structurally could not show, rather than a substitute for a placebo-controlled outcomes trial.

Beyond MACE: Additional Findings Worth Noting

SURPASS-CVOT also reported meaningful benefits in kidney function and broader metabolic markers — outcomes that point to tirzepatide's effects extending well beyond glycemic control. Real-world data reinforce this picture. A 2025–2026 systematic review and meta-analysis of eight retrospective cohort studies (N=118,252) found tirzepatide associated with reduced risks of acute coronary syndrome (HR 0.74), heart failure (HR 0.65), stroke (HR 0.71), and all-cause mortality (HR 0.49) compared to control groups — directionally consistent with both the trial data and the imputed placebo estimates. Best Practice & Research Clinical Endocrinology & Metabolism, 2026

What This Means for GLP-1 Pathway Genetics

The cardiovascular and metabolic response to GIP/GLP-1 receptor agonism is not uniform across individuals. Genetic variation in GLP1R (the GLP-1 receptor gene), GIPR (the GIP receptor gene), FTO, and TCF7L2 — among others — influences how strongly a given individual's biology responds to GLP-1 receptor signaling pathways. This is the biological basis for the well-documented variability in weight loss, glycemic response, and cardiometabolic outcomes seen across populations using GLP-1 class agents.

Emerging research continues to build the case that genetics shape who responds most robustly to interventions that work through GLP-1 receptor mechanisms. Understanding your own GLP-1 receptor pathway genetics is not a prediction of drug response — no genetic test can make that claim. It is a baseline map of how your biology is wired in the relevant pathways, which informs the conversation with a healthcare provider before any protocol decision is made.

The PlexusDx Precision Peptide Genetic Test analyzes 14 peptide-related biological pathways, including the Weight Management pathway — which contains 33 genetic insights across genes relevant to GLP-1 receptor signaling. The Peptide Pathways Report breaks these results down pathway by pathway, providing a structured genetic profile a provider can use alongside clinical assessments when evaluating weight management options. Genetics as a guide, not a guarantee — but a guide grounded in your actual DNA.

The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways, including GLP-1 receptor signaling and weight management. It does not recommend, prescribe, or determine which peptides or medications you should use. Consult a qualified healthcare provider before beginning any peptide protocol or weight management treatment.

Ready to understand your GLP-1 pathway genetic profile? Explore the Precision Peptide Genetic Test → or add the Peptide Pathways Report to your existing PlexusDx genetic data — no new sample required.

Frequently Asked Questions

What is the SURPASS-CVOT trial and what did it find about tirzepatide?

SURPASS-CVOT was a 4.5-year, 13,299-patient cardiovascular outcomes trial comparing tirzepatide — a dual GIP/GLP-1 receptor agonist — to dulaglutide in adults with type 2 diabetes and established ASCVD. Tirzepatide met the primary non-inferiority endpoint for MACE and produced a statistically significant 16% reduction in all-cause mortality (HR 0.84; P=.002) versus dulaglutide.

What did the Diabetes Care imputed placebo analysis find, and why does it matter?

Because SURPASS-CVOT used dulaglutide — itself a cardioprotective drug — as the comparator, the headline 8% MACE reduction understates tirzepatide's true benefit versus no treatment. Using a propensity score-matched REWIND population as an imputed placebo, the adjusted analysis estimated a 28% MACE-3 reduction (HR 0.72; 95% CI 0.55–0.94; p=0.016), a 39% all-cause mortality reduction (HR 0.61; 95% CI 0.45–0.82; p=0.001), and a 30% CV death or heart failure reduction (HR 0.70; 95% CI 0.51–0.96; p=0.025).

How do genetics influence GLP-1 receptor pathway response?

Variants in genes including GLP1R, GIPR, FTO, and TCF7L2 influence receptor expression, downstream signaling efficiency, and individual metabolic response to GLP-1 receptor pathway activity. The PlexusDx Precision Peptide Genetic Test analyzes the Weight Management pathway across 33 genetic insights — mapping the underlying biology a provider can factor into clinical decisions, not predicting response to any specific medication.

What does the PlexusDx Peptide Pathways Report include for weight management?

The Peptide Pathways Report delivers 33 genetic insights within the Weight Management pathway, drawn from 57 unique SNPs across 48 genes analyzed on the Illumina Global Screening Array through CLIA-certified labs. It provides a structured, pathway-by-pathway genetic profile formatted for use in conversation with a qualified healthcare provider.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education →